GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Standalone Financial Statements for the year ended March 31, 2022 140 Note 33 : Changes in inventories of Finished Goods, Stock-in-Trade and Work-In- Progress ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 Opening stock Finished goods* 108,23.54 85,80.35 Stock-in-trade 313,38.13 280,02.46 Work-in-progress 1,06.14 30,72.62 422,67.81 396,55.43 Less: Closing stock Finished goods* 135,85.00 108,23.54 Stock-in-trade 272,27.35 313,38.13 Work-in-progress 72.86 1,06.14 408,85.21 422,67.81 13,82.60 (26,12.38) * Finished goods inventory has been adjusted to give effect of discontinued operations (Refer Note 55). Note 34 : Employee benefits expense ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 Salaries, wages and bonus 559,17.25 563,60.56 Contributions to : Provident and pension funds (Refer Note 41) 23,14.96 24,51.01 Gratuity funds (Refer Note 41) 8,53.87 8,93.70 Staff welfare expense 19,37.05 19,10.74 610,23.13 616,16.01 Note 35 : Finance Costs ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 On Security deposits 25.28 34.99 Interest in respect of financial lease liability 1,73.70 3,18.15 1,98.98 3,53.14 Note 36 : Depreciation and amortization expense ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 On Property, Plant and Equipment* (Refer Note 3) 43,81.57 53,57.77 On Investment Properties (Refer Note 4) 14.38 14.38 On Other Intangible assets (Refer Note 5) 9,46.96 9,03.35 On Right to use Assets (Building) (Refer Note 48) 14,75.69 15,84.99 68,18.60 78,60.49 * Depreciation has been adjusted to give effect for discontinued operations. (Refer Note 55).